Divi's Laboratories rose 1.4% to Rs 1,132.70 at 10:21 IST on BSE after net profit jumped 63.2% to Rs 167.38 crore on 29.7% growth in net sale to Rs 468.41 crore in Q1 June 2012 over Q1 June 2011.
The company announced the results on Saturday, 4 August 2012.
Meanwhile, the BSE Sensex was up 239.50 points or 1.39% to 17,437.43.
On BSE, 5,826 shares were traded in the counter as against average daily volume of 20,716 shares over the past one quarter.
The stock hit a high of Rs 1,135 so far during the day, which is a record high for the counter. The stock hit a low of Rs 1,121 so far during the day. The stock had hit a 52-week low of Rs 690 on 26 August 2011.
The large-cap stock had outperformed the market over the past one month till 3 August 2012, surging 8.7% compared with the Sensex's 1.31% fall. The scrip had also outperformed the market in past one quarter, jumping 29.09% as against Sensex's 0.27% rise.
More From This Section
The company has an equity capital of Rs 26.55 crore. Face value per share is Rs 2.
Divi's Laboratories said its Unit-2 near Visakhapatnam has undergone 3 cGMP inspections during June-July 2012. One of the inspections was by TGA of Australia for active pharma ingredients. The other 2 inspections were by US Food and Drug Administration (USFDA), one for nutraceuticals and the other for active pharma ingredients. All the 3 inspections had no major observations, Divi's said in a statement.
Divi's Laboratories' product portfolio comprises generic active pharmaceutical ingredients (APIs) and custom synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants. Custom synthesis also includes peptide building blocks (protected amino acids).
Powered by Capital Market - Live News